Xilio Therapeutics, Inc. XLO
8.71 USD +0.03 (+0.35%)
At closeNov 4, 2026, 4:00 PM EST
8.65 -0.06 -0.69%
After hours · Nov 4, 4:00 PM ET
8.43 Day range 8.86
6.47 52-week range 11.90
- YTD
- -2.79%
- 1 year
- -22.44%
Financial health
Altman Z-Score
-2.71 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
B-2 / 5 overall
- DCF 5
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 3
- P/E 1
- P/B 3
Valuation
P/E -2.1×
FY 2019 5y median -0.9× FY 2025
P/S 1.7×
FY 2019 5y median 0.0× FY 2025
P/B 2.1×
FY 2019 5y median 0.7× FY 2025
P/FCF -13.6×
FY 2019 5y median -1.1× FY 2025
EV/EBITDA 1.7×
FY 2019 5y median 0.3× FY 2025
EV/Sales -1.3×
FY 2019 5y median 0.0× FY 2025
FCF Yield -7.4%
FY 2019 5y median -91.2% FY 2025
Profitability
Gross Margin 96.5%
FY 2019 5y median 0.0% FY 2025
Operating Margin -95.9%
FY 2019 5y median 0.0% FY 2025
Net Margin -80.1%
FY 2019 5y median 0.0% FY 2025
ROE -99.3%
FY 2019 5y median -99.3% FY 2025
ROIC -42.1%
FY 2019 5y median -71.0% FY 2025
ROA -22.6%
FY 2019 5y median -63.4% FY 2025
Growth (YoY)
Revenue 589.9%
FY 2019 FY 2025
Operating Income 30.7%
FY 2019 FY 2025
EPS (diluted) 72.5%
FY 2019 FY 2025
Free Cash Flow 70.1%
FY 2019 FY 2025
Financial Health
Current Ratio 2.6×
FY 2019 5y median 3.0× FY 2025
Quick Ratio 2.6×
FY 2019 5y median 3.0× FY 2025
Debt / Equity 0.2×
FY 2019 5y median 0.2× FY 2025
Net Debt / EBITDA 3.9×
FY 2019 5y median 1.2× FY 2025
Interest Coverage 0.0×
FY 2019 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2019 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2019 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31